-
New EU rules on medical devices set to strengthen patient safety
| 26 May 2021 |
Today new EU rules on medical devices enter into force. The new rules aim to strengthen patient safety and ensure that patients can benefit from new innovative devices. Medical devices cover anything from contact lenses to state-of-the-art surgical equipment.
-
Dean of Aarhus University to join the Danish Medicines Agency as new Director General
| 26 May 2021 |
The Ministry of Health has appointed Lars Bo Nielsen, Dean at Aarhus University, as Director General of the Danish Medicines Agency. Lars Bo Nielsen is a qualified doctor and has extensive leadership experience within both the health and science areas.
-
Danes know how vaccines work, but they underestimate how common mild side effects are
| 25 May 2021 |
A new population survey shows that Danes are generally well-informed when it comes to how COVID-19 vaccines prevent the disease. But almost half of Danes underestimate how many get mild, transient side effects, such as fever, after their COVID-19 vaccination.
-
More than one in two young people say the COVID-19 vaccine debate is characterised by misinformation
| 25 May 2021 |
In a new survey, more than half of the 16 to 34-year-olds find that the vaccine debate is characterised by misinformation, and that the tone is negative. The Danish Medicines Agency is now stepping up its ‘think before you share campaign’ (#TænkFørDuDeler) – a campaign encouraging people to check facts and to respect other people on social media.
-
New survey: Four in ten Danes would contact their doctor if they develop fever after COVID-19 vaccination
| 25 May 2021 |
Almost four in ten Danes say in a population survey that they would contact their doctor if they develop fever as a side effect after the COVID-19 vaccine jab. Theoretically, this corresponds to up to half a million Danes when everyone has been fully vaccinated.
-
Guidance on the implementation of decentralised elements in clinical trials with medicinal products is now available
| 04 May 2021 |
Decentralised clinical trials with medicinal products meet the patients, wherever they are, in a faster and more efficient process benefitting both patient, healthcare professionals and industry. It is therefore gratifying to be able to announce that another important milestone has been reached in the Danish Medicines Agency's project to ensure an up-to-date and robust regulatory framework for decentralisation of clinical trials.
